Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sema-Lit: Oral Semaglutide for Liver Fat in Transplant Recipients
NCT06060392Recruiting
- Sponsor
- Medanta
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of semaglutide in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Medanta. Primary endpoint: Change in liver fat content at 24 weeks. Started Oct 2023; status: recruiting.
02
Drugs
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06060392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06060392.